Stock COH COCHLEAR LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Cochlear Limited

Equities

COH

AU000000COH5

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E.
Other stock markets
 02:10:45 2024-04-19 am EDT 		5-day change 1st Jan Change
315.6 AUD -1.02% Intraday chart for Cochlear Limited -1.38% +5.69%
Apr. 19 Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old CI
Apr. 04 Competition Regulator Clears Cochlear’s Acquisition of Oticon Medical’s Cochlear Implant Business MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Cochlear Limited

Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old CI
Competition Regulator Clears Cochlear’s Acquisition of Oticon Medical’s Cochlear Implant Business MT
Miners, healthcare firms push Australia stocks higher RE
Sensorion: study results in hearing loss CF
Morgan Stanley Adjusts Cochlear’s Price Target to AU$276 From AU$258, Keeps at Underweight MT
Jarden Research Adjusts Cochlear’s Price Target to AU$244.35 From AU$237.17, Keeps at Neutral MT
Cochlear's Revenue Soars on Sales Growth MT
Australian Shares Flat as Mining, Financials Rally Offset Other Sectors' Losses MT
Cochlear Shares Slip 2%; Expects 26% Rise in Full Year Net Profit After Increase in H1 FY24 Profit, Revenue MT
Transcript : Cochlear Limited, H1 2024 Earnings Call, Feb 19, 2024
Cochlear Posts Rise in H1 FY24 Profit, Revenue MT
Correction: --Cochlear Reports Half Year FY24 Revenue Up 24% to AU$1.1 Billion; EPS of AU$2.913 MT
Cochlear Reports Half Year FY24 Revenue Up Down 24% to AU$1.1 Billion; EPS of AU$2.913 MT
Tranche Update on Cochlear Limited's Equity Buyback Plan announced on February 15, 2023. CI
Cochlear Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Cyclopharm Appoints CFO; Shares Rise 3% MT
Australia shares slip as biotech firm CSL slumps on failed drug trial (Feb 12) RE
Australian shares post first weekly fall in three as rate-hike bets back in focus RE
Jarden Research Adjusts Cochlear's Price Target to AU$237.17 From AU$229.20, Keeps at Neutral MT
Cochlear Upgrades Fiscal 2024 Profit Guidance; Shares Up 5% MT
Transcript : Cochlear Limited - Analyst/Investor Day
Transcript : Cochlear Limited - Shareholder/Analyst Call
Australia's CSL tanks as Novo Nordisk's kidney trial success stokes competition concerns RE
European Commission OKs Cochlear's Aquisition of Oticon Medical Unit MT
Cochlear Limited Introduces Next Generation Cochlear Osia System with Ability to Have MRI at 3.0 T CI

Chart Cochlear Limited

Chart Cochlear Limited
More charts

Company Profile

Cochlear Limited is an Australia-based company, which provides implantable hearing solutions and sound processors. The Company is engaged in development, manufacture and commercialization of implantable hearing solutions. Its segments include Cochlear implants, Services (sound processor upgrades and other) and Acoustics. The Company’s products and services portfolio include Cochlear implant portfolio, Acoustic solutions portfolio, and Recipient support tools. Its Cochlear Connected Care solutions include Cochlear Nucleus SmartNav System, Cochlear Custom Sound Pro Fitting Software, Cochlear Link, Cochlear Remote Assist, and Cochlear Remote Check solution for cochlear implants. Its Cochlear implant portfolio include Cochlear Nucleus System. Its Acoustic solutions portfolio include Cochlear Osia System, and Cochlear Baha System. Its Recipient support tools include Cochlear Nucleus, Baha and Osia Smart Apps and Cochlear CoPilot App.
Sector
Medical Equipment, Supplies & Distribution
Calendar
2024-08-14 - Q4 2024 Earnings Release
Related indices
S&P/ASX 200
More about the company

Income Statement Evolution

More financial data

Ratings for Cochlear Limited

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
16
Last Close Price
315.6 AUD
Average target price
280.9 AUD
Spread / Average Target
-11.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Prosthetics

1st Jan change Capi.
COCHLEAR LIMITED Stock Cochlear Limited
+5.69% 13.45B
STRAUMANN HOLDING AG Stock Straumann Holding AG
-1.84% 23.52B
SONOVA HOLDING AG Stock Sonova Holding AG
-9.62% 16.27B
DEMANT A/S Stock Demant A/S
+6.62% 9.68B
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD. Stock Eyebright Medical Technology (Beijing) Co., Ltd.
-21.76% 2.01B
EMBLA MEDICAL HF. Stock Embla Medical hf.
+12.20% 1.8B
ANGELALIGN TECHNOLOGY INC. Stock Angelalign Technology Inc.
+30.15% 1.62B
MODERN DENTAL GROUP LIMITED Stock Modern Dental Group Limited
+8.37% 570M
ANGEL ROBOTICS CO., LTD. Stock Angel Robotics Co., Ltd.
0.00% 524M
INTEGRUM AB Stock Integrum AB
+29.68% 96.53M
Medical Prosthetics
  1. Stock Market
  2. Equities
  3. COH Stock
  4. News Cochlear Limited
  5. Cochlear : Promotes Non-Executive Director to Chairman